Robeco Institutional Asset Management B.V. Boosts Stock Position in Alkermes plc $ALKS

Robeco Institutional Asset Management B.V. grew its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 18.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 134,387 shares of the company’s stock after buying an additional 21,067 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Alkermes were worth $4,032,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Armstrong Advisory Group Inc. acquired a new stake in Alkermes in the second quarter valued at $29,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Alkermes in the 2nd quarter worth about $49,000. Osaic Holdings Inc. raised its stake in shares of Alkermes by 56.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after purchasing an additional 701 shares in the last quarter. EMC Capital Management bought a new position in shares of Alkermes during the second quarter worth about $69,000. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Alkermes during the second quarter worth about $82,000. Institutional investors own 95.21% of the company’s stock.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $30.38, for a total value of $273,420.00. Following the sale, the executive vice president owned 69,740 shares in the company, valued at approximately $2,118,701.20. This trade represents a 11.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have sold 34,748 shares of company stock valued at $1,048,830. 4.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ALKS shares. Royal Bank Of Canada boosted their price objective on Alkermes from $45.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. HC Wainwright reiterated a “neutral” rating on shares of Alkermes in a report on Wednesday, October 22nd. Zacks Research cut Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Wells Fargo & Company lowered their target price on shares of Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.69.

Alkermes Price Performance

Shares of ALKS opened at $29.66 on Friday. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.45. The stock has a fifty day moving average price of $29.26 and a 200 day moving average price of $29.05. The company has a market cap of $4.90 billion, a P/E ratio of 14.68 and a beta of 0.48.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.08. The company had revenue of $394.19 million during the quarter, compared to the consensus estimate of $355.23 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. As a group, research analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current year.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.